US OptionsDetailed Quotes
COGT250516C11000
- 0.50
- 0.000.00%
15min DelayClose May 2 15:55 ET
0.00High0.00Low
0.50Open0.50Pre Close0 Volume8 Open Interest11.00Strike Price0.00Turnover349.94%IV95.91%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type0.2777Delta0.0846Gamma11.74Leverage Ratio-0.0492Theta0.0004Rho3.26Eff Leverage0.0038Vega
Cogent Biosciences Stock Discussion
Breakthrough: Cogent's Cancer Drug Achieves 90% Tumor Inhibition, Plus 3 More Pipeline Advances
Cogent's Cancer Breakthrough: 4 Precision Therapies Target KRAS, HER2, and Drug Resistance
loading...
based on a quick AI research:
AdvSM is very rare. Estimated 5,000-10,000 patients in US. Limited total market size.
Based on the recent clinical data, here are Cogent Biosciences' potential advantages:
1. Efficacy Advantages:
◦ 83% ORR (mIWG criteria)
◦ 100% ORR (PPR criteria)
– Higher response rate at optimal dose (100mg BID):
– Quick response time (2.2 months)
– Potentially better than existing treatments
1. Potential Market Differentiati...
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Positive
Strong 83% ORR in 100 mg BID dose cohort
94% of patients achieved ≥50% reduction in serum tryptase levels
Rapid median time to response of 2.2 months
82% progression-free survival rate at 24 months
100% of evaluable patients achieved ≥50% reduction in bone marrow mast cell burden
Negative
12 pat...
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID
88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID
Median time to response 2.2 months with median duration of response and median PFS not yet reach...
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activ...
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...
No comment yet